Becotatug Vedotin Plus Immunotherapy and Radiation for Recurrent Nasopharyngeal Cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of three treatments—a targeted cancer drug (becotatug vedotin), an immunotherapy drug (PD-1 antibody), and radiation therapy—for nasopharyngeal cancer that has come back after initial treatment. The goal is to see if this combination can shrink the tumor and help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer came back more than 12 months after your first radiation therapy, with no other cancer treatment in between
- You have measurable tumor that can be seen on imaging scans
- You are between 18 and 70 years old with good overall health (ECOG score 0–1)
- Your blood counts, liver function, kidney function, and heart function are adequate for treatment
- You are willing to use reliable birth control during treatment and for 6 months after your last dose
- You have not had recent chemotherapy, immunotherapy, or surgery that would interfere with this trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This Phase 2 trial studies whether adding toripalimab (an immune therapy) to radiation can control nasopharyngeal cancer that has spread only to a few places. It may help by boosting the immune system while the radiation treats the tumor sites.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This Phase 2 trial studies whether adding camrelizumab (an immune medicine) to stereotactic body radiation (focused, high-precision radiation) helps people with recurrent or metastatic nasopharyngeal cancer. It aims to improve control of the cancer (and may use blood EBV levels to help track response).
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.